Oramed Pharmaceuticals (ORMP) Total Liabilities (2011 - 2026)

Oramed Pharmaceuticals' Total Liabilities history runs 16 years deep, the most recent figure standing at $268.8 million for Q1 2026.

• Quarterly Total Liabilities rose 82.22% year-over-year to $268.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $268.8 million (up 82.22% YoY) and the FY2025 annual result came in at $230.9 million, up 48.68% from the prior year.
• Total Liabilities was $268.8 million for Q1 2026 at Oramed Pharmaceuticals, up from $230.9 million in the prior quarter.
• Across five years, Total Liabilities topped out at $268.8 million in Q1 2026 and bottomed at $147.5 million in Q1 2025.
• A 5-year average of $186.2 million and a median of $165.1 million in 2024 frame the typical range for Total Liabilities.
• Annual changes were most pronounced in 2024 — Total Liabilities decreased 29.6% — and 2026, when it jumped 82.22%.
• Oramed Pharmaceuticals' Total Liabilities stood at $161.6 million in 2022, then surged by 36.44% to $220.6 million in 2023, then fell by 29.6% to $155.3 million in 2024, then surged by 48.68% to $230.9 million in 2025, then increased by 16.45% to $268.8 million in 2026.
• Business Quant data shows ORMP's Total Liabilities at $268.8 million in Q1 2026, $230.9 million in Q4 2025, and $220.5 million in Q3 2025.